Climb Bio, Inc. · Nasdaq · Pharmaceutical Preparations
The filing, accepted before the open Monday, reported initial Phase 2 results for budoprutug in primary membranous nephropathy, and no source ties the decline to a specific item in it.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 15, 2026 | Stephen Basil Thomas director | Sold 10b5-1 plan | 100,000 | $13.67 | $1.37 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedClimb Bio (CLYM) Reports Initial PrisMN Phase 2 Budoprutug Data in pMN: 70% Mean PLA2R Reduction and 38% Immunologic Remission at Week 12 in 200 mg Cohort
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedClimb Bio Reports Additional CLYM116 Phase 1 Data: ~33-Day Half-Life and ~70% Gd-IgA1 Reduction at 12 Weeks
Regulation FD disclosure · Financial statements and exhibits